Qoolabs Inc.
Carlsbad, CA
- UEI
- K7HZKKAMVHK5
- CAGE
- 6NLR3
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 1915 Aston Ave, Carlsbad, CA 92008, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Affinity reagents for the immune system of guinea pigs IL1B, IL2, IL4, IL6, IL8, IL10, IL12, and IL13. | National Institute of Allergy and Infectious Diseases | $1,500,000 | |
| Sbir 133 - qoolabs | National Institute of Allergy and Infectious Diseases | $300,000 | |
| Sbir phase II | National Institute of Allergy and Infectious Diseases | $1,500,000 | |
| Sbir topic 118: reagents for immunologic analysis of non-mammalian and underrepresented mammalian models. | National Institute of Allergy and Infectious Diseases | $600,000 | |
| Sbir topic 107 affinity reagents for the immune system of golden hamster | National Institute of Allergy and Infectious Diseases | $600,000 |
About Qoolabs Inc.
Qoolabs Inc. is a woman-owned small disadvantaged business located in Carlsbad, California, specializing in developing advanced medical technologies, diagnostic tools, and research reagents for immunological and infectious disease applications. Registered in SAM.gov since 2012, the company focuses on producing high-precision affinity reagents, antibodies, and innovative diagnostic technologies primarily for government research agencies. The company has demonstrated expertise in developing medical research tools, particularly in areas related to immunology, infectious diseases, and point-of-care testing technologies.
Through federal contract awards, Qoolabs Inc. has consistently worked with the National Institute of Allergy and Infectious Diseases (NIAID) and the National Cancer Institute (NCI), receiving multiple Small Business Innovation Research (SBIR) contracts totaling millions of dollars. These contracts have covered a diverse range of research and development projects, including the production of affinity reagents for immune system studies in various animal models such as guinea pigs, golden hamsters, and swine. The company has developed specialized research tools like monoclonal antibodies, diagnostic test kits, and rapid antigen detection assays. Most of their contract awards were set aside for small businesses, with contract values ranging from $300,000 to $1,500,000, focusing on innovative medical research technologies related to infectious diseases, immunology, and potential COVID-19 testing solutions.
In terms of grant awards, Qoolabs Inc. has participated in federal grant sub-awards, notably collaborating with the University of California, Los Angeles on developing lateral flow immunoassay (LFIA) rapid tests for SARS-CoV-2 virus detection. Their grant work has centered on creating point-of-care diagnostic technologies, specifically focusing on developing rapid antigen detection methods using proprietary techniques. The company has demonstrated capability in creating innovative testing methodologies, including developing monoclonal rabbit antibodies specific to viral proteins and implementing unique viral particle disruption techniques. Their grant-related work emphasizes creating affordable, easy-to-use diagnostic solutions that can be quickly deployed for public health needs, particularly in infectious disease detection and research.
Quick answers
What is Qoolabs Inc.'s UEI?
Qoolabs Inc.'s Unique Entity ID (UEI) in SAM.gov is K7HZKKAMVHK5.
What is Qoolabs Inc.'s CAGE code?
Qoolabs Inc.'s CAGE code is 6NLR3.
What is Qoolabs Inc.'s primary NAICS code?
Qoolabs Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Qoolabs Inc. located?
Qoolabs Inc.'s physical address in SAM.gov is 1915 Aston Ave, Carlsbad, CA 92008, USA.
Is Qoolabs Inc. registered in SAM.gov?
Qoolabs Inc.'s SAM.gov registration expired on September 10, 2026.
What is Qoolabs Inc.'s most recent federal award?
Qoolabs Inc.'s most recent federal contract award is Affinity reagents for the immune system of guinea pigs IL1B, IL2, IL4, IL6, IL8, IL10, IL12, and IL13 (75N93025C00012), from National Institute of Allergy and Infectious Diseases, on February 1, 2025.
On GovTribe
See Qoolabs Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors